Effect of GH/IGF-1 on Bone Metabolism and Osteoporsosis

International Journal of Endocrinology

Volumn 2014, Issue , 2014, Pages

  Locatelli, Vittorio ^a   Bianchi, Vittorio E ^b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b Endocrinology Department   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ESTROGEN; GLUCOCORTICOID; GROWTH HORMONE; PLACEBO; RECOMBINANT GROWTH HORMONE; RECOMBINANT SOMATOMEDIN C; RINFABATE; SOMATOMEDIN C;

ACROMEGALY; AGING; ANOREXIA; ANOREXIA NERVOSA; ARTICLE; BONE GROWTH; BONE METABOLISM; CANCER RISK; CARPAL TUNNEL SYNDROME; CLINICAL TRIAL (TOPIC); CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG EFFICACY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FLUID RETENTION; FRACTURE HEALING; GROWTH HORMONE DEFICIENCY; GROWTH RETARDATION; HIGH RISK POPULATION; HIP FRACTURE; HORMONE ACTION; HORMONE RELEASE; HORMONE RESISTANCE; HORMONE SYNTHESIS; HUMAN; INTRACELLULAR SIGNALING; LOW DRUG DOSE; MECHANOTRANSDUCTION; MOLECULAR INTERACTION; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; OUTCOME ASSESSMENT; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENILE OSTEOPOROSIS; SIDE EFFECT; TIBIA FRACTURE; TREATMENT DURATION;

EID: 84923057002     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2014/235060     Document Type: Article

References (314)

1. R. Bouillon and A. Prodonova, "Growth hormone deficiency and peak bone mass", Journal of Pediatric Endocrinology & Metabolism, vol. 13, supplement 6, pp. 1327-1336, 2000.
2. A. M. Boot, M. A. M. J. Engels, G. J. M. Boerma, E. P. Krenning, and S. M. P. F. de Muinck Keizer-Schrama, "Changes in bone mineral density, body composition, and lipid metabolism during growth hormone (GH) treatment in children with GH deficiency", Journal of Clinical Endocrinology and Metabolism, vol. 82, no. 8, pp. 2423-2428, 1997.
3. A. Giustina, G. Mazziotti, and E. Canalis, "Growth hormone, insulin-like growth factors, and the skeleton", Endocrine Reviews, vol. 29, no. 5, pp. 535-559, 2008.
4. E. Barrett-Connor and D. Goodman-Gruen, "Gender differences in insulin-like growth factor and bone mineral density association in old age: the rancho Bernardo study", Journal of Bone and Mineral Research, vol. 13, no. 8, pp. 1343-1349, 1998.
5. J. A. Langlois, C. J. Rosen, M. Visser et al., "Association between insulin-like growth factor I and bone mineral density in older women and men: the Framingham heart study", Journal of Clinical Endocrinology and Metabolism, vol. 83, no. 12, pp. 4257-4262, 1998.
6. J. A. M. J. L. Janssen, H. Burger, R. P. Stolk et al., "Genderspecific relationship between serum free and total IGF-I and bone mineral density in elderly men and women", European Journal of Endocrinology, vol. 138, no. 6, pp. 627-632, 1998.
7. A. G. Johansson, A. Forslund, L. Hambraeus, W. F. Blum, and S. Ljunghall, "Growth hormone-dependent insulin-like growth factor binding protein is a major determinant of bone mineral density in healthy men", Journal of Bone and Mineral Research, vol. 9, no. 6, pp. 915-921, 1994.
8. T. Sugimoto, K. Nishiyama, F. Kuribayashi, and K. Chihara, "Serum levels of insulin-like growth factor (IGF) I, IGF-binding protein (IGFBP)-2, and IGFBP-3 in osteoporotic patients with and without spinal fractures", Journal of Bone and Mineral Research, vol. 12, no. 8, pp. 1272-1279, 1997.
9. P. Garnero, E. Sornay-Rendu, and P. D. Delmas, "Low serum IGF-1 and occurrence of osteoporotic fractures in postmenopausal women", The Lancet, vol. 355, no. 9207, pp. 898-899, 2000.
10. C. Ohlsson, D. Mellström, D. Carlzon et al., "Older men with low serum IGF-1 have an increased risk of incident fractures: the MrOS Sweden study", Journal of Bone and Mineral Research, vol. 26, no. 4, pp. 865-872, 2011.
11. I. Kanazawa, T. Yamaguchi, M. Yamamoto, M. Yamauchi, S. Yano, and T. Sugimoto, "Seruminsulin-like growth factor-I level is associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes mellitus", Osteoporosis International, vol. 18, no. 12, pp. 1675-1681, 2007.
12. P. R. Ebeling, L. M. Atley, J. R. Guthrie et al., "Bone turnover markers and bone density across the menopausal transition", Journal of Clinical Endocrinology & Metabolism, vol. 81, no. 9, pp. 3366-3371, 1996.
13. K. Y. Ho, W. S. Evans, R. M. Blizzard et al., "Effects of sex and age on the 24-hour profile of growth hormone secretion inman: importance of endogenous estradiol concentrations", Journal of Clinical Endocrinology and Metabolism, vol. 64, no. 1, pp. 51-58, 1987.
14. P. Szulc, M. O. Joly-Pharaboz, F. Marchand, and P. D. Delmas, "Insulin-like growth factor I is a determinant of Hip bone mineral density inmen less than 60 years of age: MINOS study", Calcified Tissue International, vol. 74, no. 4, pp. 322-329, 2004.
15. E. Seeman, "Estrogen, androgen, and the pathogenesis of bone fragility in women and men", Current Osteoporosis Reports, vol. 2, no. 3, pp. 90-96, 2004.
16. M. Almeida, L. Han, M. Martin-Millan et al., "Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids", Journal of Biological Chemistry, vol. 282, no. 37, pp. 27285-27297, 2007.
17. S. Yakar, H. Courtland, and D. Clemmons, "IGF-1 and bone: new discoveries from mouse models", Journal of Bone and Mineral Research, vol. 25, no. 12, pp. 2543-2552, 2010.
18. J. C. Fritton, K. B. Emerton, H. Sun et al., "Growth hormone protects against ovariectomy-induced bone loss in states of low circulating Insulin-like Growth Factor (IGF-1)", Journal of Bone and Mineral Research, vol. 25, no. 2, pp. 235-246, 2010.
19. A. Giustina and J. D. Veldhuis, "Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human", Endocrine Reviews, vol. 19, no. 6, pp. 717-797, 1998.
20. J. R. Florini, D. Z. Ewton, and S. A. Coolican, "Growth hormone and the insulin-like growth factor system in myogenesis", Endocrine Reviews, vol. 17, no. 5, pp. 481-517, 1996.
21. S. Feld and R. Hirschberg, "Insulinlike growth factor I and the kidney", Trends in Endocrinology & Metabolism, vol. 7, no. 3, pp. 85-93, 1996.
22. G. Goldspink and S. D. R. Harridge, "Growth factors andmuscle ageing", Experimental Gerontology, vol. 39, no. 10, pp. 1433-1438, 2004.
23. D. Aberg, "Role of the growth hormone/insulin-like growth factor 1 axis in neurogenesis", Endocrine Development, vol. 17, pp. 63-76, 2010.
24. C. Ohlsson, B. Bengtsson, O. G. P. Isaksson, T. T. Andreassen, and M. C. Slootweg, "Growth hormone and bone", Endocrine Reviews, vol. 19, no. 1, pp. 55-79, 1998.
25. M. Ballesteros, K. Leung, R. J. M. Ross, T. P. Iismaa, and K. K. Y. Ho, "Distribution and abundance of messenger ribonucleic acid for growth hormone receptor isoforms in human tissues", Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 8, pp. 2865-2871, 2000.
26. S. Yakar, J.-L. Liu, B. Stannard et al., "Normal growth and development in the absence of hepatic insulin-like growth factor I", Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 13, pp. 7324-7329, 1999.
27. J.-P. Liu, J. Baker, A. S. Perkins, E. J. Robertson, and A. Efstratiadis, "Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r)", Cell, vol. 75, no. 1, pp. 59-72, 1993.
28. K. Sjögren, J. Liu, K. Blad et al., "Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice", Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 12, pp. 7088-7092, 1999.
29. J. Holly and C. Perks, "The role of insulin-like growth factor binding proteins", Neuroendocrinology, vol. 83, no. 3-4, pp. 154-160, 2006.
30. C. J. Rosen, L. R. Donahue, and S. J. Hunter, "Insulin-like growth factors and bone: the osteoporosis connection", Proceedings of the Society for Experimental Biology and Medicine, vol. 206, no. 2, pp. 83-102, 1994.
31. N. Goldenberg and A. Barkan, "Factors regulating growth hormone secretion in humans", Endocrinology and Metabolism Clinics of North America, vol. 36, no. 1, pp. 37-55, 2007.
32. J. I. Jones and D. R. Clemmons, "Insulin-like growth factors and their binding proteins: biological actions", Endocrine Reviews, vol. 16, no. 1, pp. 3-34, 1995.
33. C. M. Bagi, R. Brommage, L. Deleon, S. Adams, D. Rosen, and A. Sommer, "Benefit of systemically administered rhIGF-I and rhIGF-I/IGFBP-3 on cancellous bone in ovariectomized rats", Journal of Bone and Mineral Research, vol. 9, no. 8, pp. 1301-1312, 1994.
34. C. Carter-Su and L. S. Smit, "Signaling via JAK tyrosine kinases: growth hormone receptor as a model system", Recent Progress in Hormone Research, vol. 53, pp. 61-83, 1998.
35. S. F. Ahmed and C. Farquharson, "The effect of GHand IGF1 on linear growth and skeletal development and their modulation by SOCS proteins", Journal of Endocrinology, vol. 206, no. 3, pp. 249-259, 2010.
36. V. E. Macrae, S. Horvat, S. C. Pells et al., "Increased bone mass, altered trabecular architecture andmodified growth plate organization in the growing skeleton of SOCS2 deficient mice", Journal of Cellular Physiology, vol. 218, no. 2, pp. 276-284, 2009.
37. P. Bang, M. Westgren, J. Schwander, W. F. Blum, R. G. Rosenfeld, and M. Stangenberg, "Ontogeny of insulin-like growth factorbinding protein-1, -2, and -3: quantitative measurements by radioimmunoassay in human fetal serum", Pediatric Research, vol. 36, no. 4, pp. 528-536, 1994.
38. G. P. Baumann, "Growth hormone isoforms", Growth Hormone and IGF Research, vol. 19, no. 4, pp. 333-340, 2009.
39. J. Frystyk, P. Freda, and D. R. Clemmons, "The current status of IGF-I assays-a 2009 update", Growth Hormone & IGF Research, vol. 20, no. 1, pp. 8-18, 2010.
40. I. Bancos, A. Algeciras-Schimnich, W. W. Woodmansee et al., "Determination of nadir growth hormone concentration cutoff in patients with acromegaly", Endocrine Practice, vol. 19, no. 6, pp. 937-945, 2013.
41. A. W. van Toorenenbergen, "Between-laboratory quality control of automated analysis of IgG antibodies against Aspergillus fumigatus", Diagnostic Microbiology and Infectious Disease, vol. 74, no. 3, pp. 278-281, 2012.
42. J. D. Faix, "Principles and pitfalls of free hormone measurements", Best Practice & Research Clinical Endocrinology & Metabolism, vol. 27, no. 5, pp. 631-645, 2013.
43. W. D. Salmon Jr. and W. H. Daughaday, "A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro", The Journal of Laboratory and Clinical Medicine, vol. 49, no. 6, pp. 825-836, 1957.
44. N. L. Schlechter, S. M. Russell, S. Greenberg, E. M. Spencer, and C. S. Nicoll, "A direct growth effect of growth hormone in rat hindlimb shown by arterial infusion", American Journal of Physiology-Endocrinology and Metabolism, vol. 250, no. 3, part 1, pp. E231-E235, 1986.
45. H. Green, M. Morikawa, and T. Nixon, "A dual effector theory of growth-hormone action", Differentiation, vol. 29, no. 3, pp. 195-198, 1985.
46. A. Lindahl, J. Isgaard, A. Nilsson, and O. G. P. Isaksson, "Growth hormone potentiates colony formation of epiphyseal chondrocytes in suspension culture", Endocrinology, vol. 118, no. 5, pp. 1843-1848, 1986.
47. C. Ohlsson, A. Nilsson, O. Isaksson, and A. Lindahl, "Growth hormone induces multiplication of the slowly cycling germinal cells of the rat tibial growth plate", Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 20, pp. 9826-9830, 1992.
48. M. Kassem, L. Mosekilde, and E. F. Eriksen, "Growth hormone stimulates proliferation of normal human bone marrowstromal osteoblast precursor cells in vitro", Growth Regulation, vol. 4, no. 3, pp. 131-135, 1994.
49. A. Nilsson, D. Swolin, S. Enerback, and C. Ohlsson, "Expression of functional growth hormone receptors in cultured human osteoblast-like cells", The Journal of Clinical Endocrinology & Metabolism, vol. 80, no. 12, pp. 3483-3488, 1995.
50. M. Ernst and G. A. Rodan, "Increased activity of insulin-like growth factor (IGF) in osteoblastic cells in the presence of growth hormone (GH): positive correlation with the presence of the GH-induced IGF-binding protein BP-3", Endocrinology, vol. 127, no. 2, pp. 807-814, 1990.
51. Z. Laron and B. Klinger, "IGF-I treatment of adult patients with Laron syndrome: preliminary results", Clinical Endocrinology, vol. 41, no. 5, pp. 631-638, 1994.
52. M. B. Ranke, M. O. Savage, P. G. Chatelain et al., "Insulinlike growth factor I improves height in growth hormone insensitivity: two years' results", Hormone Research, vol. 44, no. 6, pp. 253-264, 1995.
53. J. L. Walker, J. J. Van Wyk, and L. E. Underwood, "Stimulation of statural growth by recombinant insulin-like growth factor I in a child with growth hormone insensitivity syndrome (Laron type)", Journal of Pediatrics, vol. 121, no. 4, pp. 641-646, 1992.
54. J. Guevara-Aguirre, A. L. Rosenbloom, O. Vasconez et al., "Twoyear treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency", Journal of Clinical Endocrinology and Metabolism, vol. 82, no. 2, pp. 629-633, 1997.
55. P. F. Collett-Solberg, M. Misra, and Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine, "The role of recombinant human insulin-like growth factor-I in treating children with short stature", Journal of Clinical Endocrinology & Metabolism, vol. 93, no. 1, pp. 10-18, 2008.
56. C. J. Rosen and J. P. Bilezikian, "Clinical review 123: anabolic therapy for osteoporosis", The Journal of Clinical Endocrinology & Metabolism, vol. 86, no. 3, pp. 957-964, 2001.
57. O. G. P. Isaksson, J. O. Jansson, and I. A. M. Gause, "Growth hormone stimulates longitudinal bone growth directly", Science, vol. 216, no. 4551, pp. 1237-1239, 1982.
58. J. Isgaard, C. Moller, O. G. P. Isaksson, A. Nilsson, L. S. Mathews, and G. Norstedt, "Regulation of insulin-like growth factor messenger ribonucleic acid in rat growth plate by growth hormone", Endocrinology, vol. 122, no. 4, pp. 1515-1520, 1988.
59. E. B. Hunziker, J. Wagner, and J. Zapf, "Differential effects of insulin-like growth factor I and growth hormone on developmental stages of rat growth plate chondrocytes in vivo", Journal of Clinical Investigation, vol. 93, no. 3, pp. 1078-1086, 1994.
60. H. P. Guler, J. Zapf, E. Scheiwiller, and E. R. Froesch, "Recombinant human insulin-like growth factor I stimulates growth and has distinct effects on organ size in hypophysectomized rats.", Proceedings of the National Academy of Sciences of the United States of America, vol. 85, no. 13, pp. 4889-4893, 1988.
61. S. R. Kupfer, L. E. Underwood, R. C. Baxter, and D. R. Clemmons, "Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously", Journal of Clinical Investigation, vol. 91, no. 2, pp. 391-396, 1993.
62. P. J. Fielder, D. L. Mortensen, P. Mallet, B. Carlsson, R. C. Baxter, and R. G. Clark, "Differential long-term effects of insulin-like growth factor-I (IGF-I), growth hormone (GH), and IGF-I plus GH on body growth and IGF binding proteins in hypophysectomized rats", Endocrinology, vol. 137, no. 5, pp. 1913-1920, 1996.
63. S. J. Hazel, C. M. Gillespie, R. J. Moore, R. G. Clark, K. F. Jureidini, and A. A. Martin, "Enhanced body growth in uremic rats treated with IGF-I and growth hormone in combination", Kidney International, vol. 46, no. 1, pp. 58-68, 1994.
64. N. A. Sims, P. Clément-Lacroix, F. da Ponte et al., "Bone homeostasis in growth hormone receptor-null mice is restored by IGF-I but independent of Stat5", The Journal of Clinical Investigation, vol. 106, no. 9, pp. 1095-1103, 2000.
65. H. Courtland, S. Elis, Y. Wu et al., "Serum IGF-1 affects skeletal acquisition in a temporal and compartment-specific manner", PLoS ONE, vol. 6, no. 3, Article ID e14762, 2011.
66. L. Laviola, A. Natalicchio, S. Perrini, and F. Giorgino, "Abnormalities of IGF-I signaling in the pathogenesis of diseases of the bone, brain, and fetoplacental unit in humans", The American Journal of Physiology: Endocrinology and Metabolism, vol. 295, no. 5, pp. E991-E999, 2008.
67. S. Yakar, E. Canalis, H. Sun et al., "Serum IGF-1 determines skeletal strength by regulating subperiosteal expansion and trait interactions", Journal of Bone and Mineral Research, vol. 24, no. 8, pp. 1481-1492, 2009.
68. M. Zhang, S. Xuan, M. L. Bouxsein et al., "Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization", Journal of Biological Chemistry, vol. 277, no. 46, pp. 44005-44012, 2002.
69. S. Yakar, C. J. Rosen, W. G. Beamer et al., "Circulating levels of IGF-1 directly regulate bone growth and density", Journal of Clinical Investigation, vol. 110, no. 6, pp. 771-781, 2002.
70. H. Uronen-Hansson, M. L. Allen, E. Lichtarowicz-Krynska et al., "Growth hormone enhances proinflammatory cytokine production by monocytes in whole blood", Growth Hormone and IGF Research, vol. 13, no. 5, pp. 282-286, 2003.
71. G. Renier, I. Clément, A. C. Desfaits, and A. Lambert, "Direct stimulatory effect of insulin-like growth factor-I on monocyte and macrophage tumor necrosis factor-α production", Endocrinology, vol. 137, no. 11, pp. 4611-4618, 1996.
72. M. Wolf, S. Bohm, M. Brand, and G. Kreymann, "Proinflammatory cytokines interleukin 1-β and tumor necrosis factor α inhibit growth hormone stimulation of insulin-like growth factor I synthesis and growth hormone receptor mRNA levels in cultured rat liver cells", European Journal of Endocrinology, vol. 135, no. 6, pp. 729-737, 1996.
73. D. Swolin and C. Ohlsson, "Growth hormone increases interleukin-6 produced by human osteoblast-like cells", Journal of Clinical Endocrinology and Metabolism, vol. 81, no. 12, pp. 4329-4333, 1996.
74. T. Yamaguchi, M. Kanatani, M. Yamauchi et al., "Serum levels of insulin-like growth factor (IGF); IGF-binding proteins-3, -4, and -5; and their relationships to bone mineral density and the risk of vertebral fractures in postmenopausal women", Calcified Tissue International, vol. 78, no. 1, pp. 18-24, 2006.
75. S. Boonen, S. Mohan, J. Dequeker et al., "Down-regulation of the serum stimulatory components of the insulin-like growth factor (IGF) system (IGF-I, IGF-II, IGF binding protein [BP]-3, and IGFBP-5) in age-related (type II) femoral neck osteoporosis", Journal of Bone and Mineral Research, vol. 14, no. 12, pp. 2150-2158, 1999.
76. T. Seck, C. Scheidt-Nave, G. Leidig-Bruckner, R. Ziegler, and J. Pfeilschifter, "Low serum concentrations of insulin-like growth factor I are associated with femoral bone loss in a populationbased sample of postmenopausal women", Clinical Endocrinology, vol. 55, no. 1, pp. 101-106, 2001.
77. G. E. Krassas, P. Papadopoulou, G. Koliakos, T. Konstantinidis, and K. Kalothetou, "Growth hormone, insulin growth factor-1, and IGF binding protein-3 axis relationship with bone mineral density among healthy men", Archives of Andrology, vol. 49, no. 3, pp. 191-199, 2003.
78. P. M. Yamada and K. W. Lee, "Perspectives in mammalian IGFBP-3 biology: local vs. systemic action", The American Journal of Physiology-Cell Physiology, vol. 296, no. 5, pp. C954-C976, 2009.
79. O. Ali, P. Cohen, and K.-W. Lee, "Epidemiology and biology of insulin-like growth factor binding protein-3 (IGFBP-3) as an anti-cancermolecule", Hormone and Metabolic Research, vol. 35, no. 11-12, pp. 726-733, 2003.
80. S. Benini, M. Zuntini, M. C. Manara et al., "Insulin-like growth factor binding protein 3 as an anticancer molecule in Ewing's sarcoma", International Journal of Cancer, vol. 119, no. 5, pp. 1039-1046, 2006.
81. I. Niemann, A. Hannemann, M. Nauck et al., "The association between insulin-like growth factor I and bone turnovermarkers in the general adult population", Bone, vol. 56, no. 1, pp. 184-190, 2013.
82. S. C. Manolagas, "Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis", Endocrine Reviews, vol. 21, no. 2, pp. 115-137, 2000.
83. M. Beato and J. Klug, "Steroid hormone receptors: an update", Human Reproduction Update, vol. 6, no. 3, pp. 225-236, 2000.
84. S. C. Manolagas, C. A. O'Brien, and M. Almeida, "The role of estrogen and androgen receptors in bone health and disease", Nature Reviews Endocrinology, vol. 9, no. 12, pp. 699-712, 2013.
85. D. S. Colvard, E. F. Eriksen, P. E. Keeting et al., "Identification of androgen receptors in normal human osteoblast-like cells", Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 3, pp. 854-857, 1989.
86. C. Ohlsson and L. V. Vandenput, "The role of estrogens formale bone health", European Journal of Endocrinology, vol. 160, no. 6, pp. 883-889, 2009.
87. H. Kawano, H. Kawaguchi, and S. Kato, "Bone metabolism in androgen receptor-deficient mice", Clinical Calcium, vol. 13, no. 11, pp. 1443-1445, 2003.
88. A. J. Notini, J. F. McManus, A. Moore et al., "Osteoblast deletion of exon 3 of the androgen receptor gene results in trabecular bone loss in adult male mice", Journal of Bone and Mineral Research, vol. 22, no. 3, pp. 347-356, 2007.
89. F. Callewaert, M. Sinnesael, E. Gielen, S. Boonen, and D. Vanderschueren, "Skeletal sexual dimorphism: relative contribution of sex steroids, GH-IGF1, and mechanical loading", Journal of Endocrinology, vol. 207, no. 2, pp. 127-134, 2010.
90. S. Kousteni, T. Bellido, L. I. Plotkin et al., "Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity", Cell, vol. 104, no. 5, pp. 719-730, 2001.
91. D. J. Benz, M. R. Haussler, M. A. Thomas, B. Speelman, and B. S. Komm, "High-affinity androgen binding and androgenic regulation of β1 (I)-procollagen and transforming growth factor-α steady state messenger ribonucleic acid levels in human osteoblast-like osteosarcoma cells", Endocrinology, vol. 128, no. 6, pp. 2723-2730, 1991.
92. J. P. Bilezikian, A. Morishima, J. Bell, and M. M. Grumbach, "Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency", The New England Journal of Medicine, vol. 339, no. 9, pp. 599-603, 1998.
93. V. Coxam, B. M. Bowman, M. Mecham, C. M. Roth, M. A. Miller, and S. C. Miller, "Effects of dihydrotestosterone alone and combined with estrogen on bone mineral density, bone growth, and formation rates in ovariectomized rats", Bone, vol. 19, no. 2, pp. 107-114, 1996.
94. A. Tomkinson, J. Reeve, R. W. Shaw, and B. S. Noble, "The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone", Journal of Clinical Endocrinology and Metabolism, vol. 82, no. 9, pp. 3128-3135, 1997.
95. M. Martin-Millan, M. Almeida, E. Ambrogini et al., "The estrogen receptor-α in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone", Molecular Endocrinology, vol. 24, no. 2, pp. 323-334, 2010.
96. S. H. Windahl, L. Saxon, A. E. Börjesson et al., "Estrogen receptor-α is required for the osteogenic response to mechanical loading in a ligand-independent manner involving its activation function 1 but not 2", Journal of Bone and Mineral Research, vol. 28, no. 2, pp. 291-301, 2013.
97. R. Marcus, D. Leary, D. L. Schneider, E. Shane, M. Favus, and C. A. Quigley, "The contribution of testosterone to skeletal development and maintenance: lessons from the androgen insensitivity syndrome", Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 3, pp. 1032-1037, 2000.
98. H. Kawano, T. Sato, T. Yamada et al., "Suppressive function of androgen receptor in bone resorption", Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 16, pp. 9416-9421, 2003.
99. K. M. Wiren, A. A. Semirale, X. W. Zhang et al., "Targeting of androgen receptor in bone reveals a lack of androgen anabolic action and inhibition of osteogenesis: a model for compartment-specific androgen action in the skeleton", Bone, vol. 43, no. 3, pp. 440-451, 2008.
100. S. Khosla, M. J. Oursler, and D. G. Monroe, "Estrogen and the skeleton", Trends in Endocrinology and Metabolism, vol. 23, no. 11, pp. 576-581, 2012.
101. A. Falahati-Nini, B. L. Riggs, E. J. Atkinson, W. M. O'Fallon, R. Eastell, and S. Khosla, "Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men", Journal of Clinical Investigation, vol. 106, no. 12, pp. 1553-1560, 2000.
102. L. Mosekilde, J. S. Thomsen, P. B. Orhii, and D. N. Kalu, "Growth hormone increases vertebral and femoral bone strength in osteopenic, ovariectomized, aged rats in a dose-dependent and site-specific manner", Bone, vol. 23, no. 4, pp. 343-352, 1998.
103. Y. Kasukawa, L. Stabnov, N. Miyakoshi, D. J. Baylink, and S. Mohan, "Insulin-like growth factor I effect on the number of osteoblast progenitors is impaired in ovariectomized mice", Journal of Bone and Mineral Research, vol. 17, no. 9, pp. 1579-1587, 2002.
104. J. K. Yeh, M. Chen, and J. F. Aloia, "Effects of estrogen and growth hormone on skeleton in the ovariectomized rat with hypophysectomy", The American Journal of Physiology - Endocrinology and Metabolism, vol. 273, no. 4, pp. E734-E742, 1997.
105. L. S. Kidder, I. U. Schmidt, G. L. Evans, and R. T. Turner, "Effects of growth hormone and low dose estrogen on bone growth and turnover in long bones of hypophysectomized rats", Calcified Tissue International, vol. 61, no. 4, pp. 327-335, 1997.
106. T. Abe, J. W. M. Chow, J. M. Lean, and T. J. Chambers, "Estrogen does not restore bone lost after ovariectomy in the rat", Journal of Bone and Mineral Research, vol. 8, no. 7, pp. 831-838, 1993.
107. G. K. Wakley, G. L. Evans, and R. T. Turner, "Short-term effects of high dose estrogen on tibiae of growingmale rats", Calcified Tissue International, vol. 60, no. 1, pp. 37-42, 1997.
108. J. D. Veldhuis, J. Frystyk, A. Iranmanesh, and H. Ørskov, "Testosterone and estradiol regulate free insulin-like growth factor I (IGF-I), IGF binding protein 1 (IGFBP-1), and dimeric IGFI/IGFBP-1 concentrations", Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 5, pp. 2941-2947, 2005.
109. A. J. Weissberger, K. K. Ho, and L. Lazarus, "Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women", Journal of Clinical Endocrinology and Metabolism, vol. 72, no. 2, pp. 374-381, 1991.
110. L. Vandenput, S. Boonen, E. Van Herck, J. V. Swinnen, R. Bouillon, and D. Vanderschueren, "Evidence fromthe aged orchidectomized male rat model that 17β-estradiol is a more effective bone-sparing and anabolic agent than 5α-dihydrotestosterone", Journal of Bone and Mineral Research, vol. 17, no. 11, pp. 2080-2086, 2002.
111. J. J. Christiansen, S. Fisker, C. H. Gravholt et al., "Discontinuation of estrogen replacement therapy in GH-treated hypopituitary women alters androgen status and IGF-I", European Journal of Endocrinology, vol. 152, no. 5, pp. 719-726, 2005.
112. D. Vanderschueren, L. Vandenput, S. Boonen, M. K. Lindberg, R. Bouillon, and C. Ohlsson, "Androgens and bone", Endocrine Reviews, vol. 25, no. 3, pp. 389-425, 2004.
113. C. H. Kasperk, J. E. Wergedal, J. R. Farley, T. A. Linkhart, R. T. Turner, and D. J. Baylink, "Androgens directly stimulate proliferation of bone cells in vitro", Endocrinology, vol. 124, no. 3, pp. 1576-1578, 1989.
114. L. X. Bi, K. M. Wiren, X. W. Zhang et al., "The effect of oxandrolone treatment on human osteoblastic cells", Journal of Burns and Wounds, vol. 6, article e4, 2007.
115. K. Venken, K. De Gendt, S. Boonen et al., "Relative impact of androgen and estrogen receptor activation in the effects of androgens on trabecular and cortical bone in growing male mice: a study in the androgen receptor knockoutmouse model", Journal of Bone and Mineral Research, vol. 21, no. 4, pp. 576-585, 2006.
116. G. Prakasam, J. K. Yeh, M. Chen, M. Castro-Magana, C. T. Liang, and J. F. Aloia, "Effects of growth hormone and testosterone on cortical bone formation and bone density in aged orchiectomized rats", Bone, vol. 24, no. 5, pp. 491-497, 1999.
117. A. J. Weissberger and K. K. Y. Ho, "Activation of the somatotropic axis by testosterone in adult males: evidence for the role of aromatization", Journal of Clinical Endocrinology and Metabolism, vol. 76, no. 6, pp. 1407-1412, 1993.
118. H. K. Gleeson and S. M. Shalet, "Effect of aromatizable and unaromatizable androgen replacement in hypogonadal men on GH responsiveness", Clinical Endocrinology, vol. 70, no. 1, pp. 109-115, 2009.
119. D. Vanderschueren, S. Boonen, A. G. H. Ederveen et al., "Skeletal effects of estrogen deficiency as induced by an aromatase inhibitor in an aged male rat model", Bone, vol. 27, no. 5, pp. 611-617, 2000.
120. D. Vanderschueren, E. Van Herck, A. M. H. Suiker, W. J. Visser, L. P. C. Schot, and R. Bouillon, "Bone and mineral metabolism in aged male rats: short and long term effects of androgen deficiency", Endocrinology, vol. 130, no. 5, pp. 2906-2916, 1992.
121. A. E. Kearns and S. Khosla, "Potential anabolic effects of androgens on bone", Mayo Clinic Proceedings, vol. 79, no. 4, pp. S14-S18, 2004.
122. C. J. Hobbs, S. R. Plymate, C. J. Rosen, and R. A. Adler, "Testosterone administration increases insulin-like growth factor-I levels in normal men", The Journal of Clinical Endocrinology & Metabolism, vol. 77, no. 3, pp. 776-779, 1993.
123. L. Liu, G. R. Merriam, and R. J. Sherins, "Chronic sex steroid exposure increases mean plasma growth hormone concentration and pulse amplitude in men with isolated hypogonadotropic hypogonadism", Journal of Clinical Endocrinology and Metabolism, vol. 64, no. 4, pp. 651-656, 1987.
124. J. O. L. Jorgensen, N. Vahl, T. B. Hansen et al., "Determinants of seruminsulin-like growth factor I in growth hormone deficient adults as compared to healthy subjects", Clinical Endocrinology, vol. 48, no. 4, pp. 479-486, 1998.
125. C. Chiang, M. Chiu, A. J. Moore et al., "Mineralization and bone resorption are regulated by the androgen receptor inmale mice", Journal of Bone and Mineral Research, vol. 24, no. 4, pp. 621-631, 2009.
126. T. L. Andersen, T. E. Sondergaard, K. E. Skorzynska et al., "A physical mechanism for coupling bone resorption and formation in adult human bone", The American Journal of Pathology, vol. 174, no. 1, pp. 239-247, 2009.
127. M. Kassem, W. Blum, J. Ristelli, L. Mosekilde, and E. F. Eriksen, "Growth hormone stimulates proliferation and differentiation of normal human osteoblast-like cells in vitro", Calcified Tissue International, vol. 52, no. 3, pp. 222-226, 1993.
128. K. Brixen, M. Kassem, H. K. Nielsen, A. G. Loft, A. Flyvbjerg, and L. Mosekilde, "Short-termtreatment with growth hormone stimulates osteoblastic and osteoclastic activity in osteopenic postmenopausal women: a dose response study", Journal of Bone and Mineral Research, vol. 10, no. 12, pp. 1865-1874, 1995.
129. V. Krishnan, H. U. Bryant, and O. A. MacDougald, "Regulation of bone mass by Wnt signaling", Journal of Clinical Investigation, vol. 116, no. 5, pp. 1202-1209, 2006.
130. H. Clevers, "Wnt/β-catenin signaling in development and disease", Cell, vol. 127, no. 3, pp. 469-480, 2006.
131. M. F. Cole, S. E. Johnstone, J. J. Newman, M. H. Kagey, and R. A. Young, "Tcf3 is an integral component of the core regulatory circuitry of embryonic stem cells", Genes and Development, vol. 22, no. 6, pp. 746-755, 2008.
132. E. Canalis, V. Deregowski, R. C. Pereira, and E. Gazzerro, "Signals that determine the fate of osteoblastic cells", Journal of Endocrinological Investigation, vol. 28, no. 8, pp. 3-7, 2005.
133. M. Takeuchi, H. Kakushi, and M. Tohkin, "Androgens directly stimulate mineralization and increase androgen receptors in human osteoblast-like osteosarcoma cells", Biochemical and Biophysical Research Communications, vol. 204, no. 2, pp. 905-911, 1994.
134. P. Hou, T. Sato, W. Hofstetter, and N. T. Foged, "Identification and characterization of the insulin-like growth factor I receptor in mature rabbit osteoclasts", Journal of Bone and Mineral Research, vol. 12, no. 4, pp. 534-540, 1997.
135. T. Niu and C. J. Rosen, "The insulin-like growth factor-I gene and osteoporosis: a critical appraisal", Gene, vol. 361, no. 1-2, pp. 38-56, 2005.
136. G. Mazziotti, A. Bianchi, S. Bonadonna et al., "Prevalence of vertebral fractures in men with acromegaly", Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 12, pp. 4649-4655, 2008.
137. T. L. McCarthy and M. Centrella, "Regulation of IGF activity in bone", Advances in Experimental Medicine and Biology, vol. 343, pp. 407-414, 1993.
138. D. P. Bichell, P. Rotwein, and T. L. McCarthy, "Prostaglandin E2 rapidly stimulates insulin-like growth factor-I gene expression in primary rat osteoblast cultures: Evidence for transcriptional control", Endocrinology, vol. 133, no. 3, pp. 1020-1028, 1993.
139. E. Canalis, M. Centrella, W. Burch, and T. L. McCarthy, "Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures", Journal of Clinical Investigation, vol. 83, no. 1, pp. 60-65, 1989.
140. T. L. McCarthy, M. Centrella, L. G. Raisz, and E. Canalis, "Prostaglandin E2 stimulates insulin-like growth factor I synthesis in osteoblast-enriched cultures from fetal rat bone", Endocrinology, vol. 128, no. 6, pp. 2895-2900, 1991.
141. R. M. Locklin, S. Khosla, R. T. Turner, and B. L. Riggs, "Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone", Journal of Cellular Biochemistry, vol. 89, no. 1, pp. 180-190, 2003.
142. T. Ishizuya, S. Yokose, M. Hori et al., "Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells", Journal of Clinical Investigation, vol. 99, no. 12, pp. 2961-2970, 1997.
143. M. Kassem and P. J. Marie, "Senescence-associated intrinsic mechanisms of osteoblast dysfunctions", Aging Cell, vol. 10, no. 2, pp. 191-197, 2011.
144. S. Amin, B. L. Riggs, L. J. Melton III, S. J. Achenbach, E. J. Atkinson, and S. Khosla, "High serum IGFBP-2 is predictive of increased bone turnover in aging men and women", Journal of Bone and Mineral Research, vol. 22, no. 6, pp. 799-807, 2007.
145. D. J. DiGirolamo, A. Mukherjee, K. Fulzele et al., "Mode of growth hormone action in osteoblasts", The Journal of Biological Chemistry, vol. 282, no. 43, pp. 31666-31674, 2007.
146. C. T. Rubin, S. D. Bain, and K. J. McLeod, "Suppression of the osteogenic response in the aging skeleton", Calcified Tissue International, vol. 50, no. 4, pp. 306-313, 1992.
147. S. L. Bass, P. Eser, and R. Daly, "The effect of exercise and nutrition on the mechanostat", Journal of Musculoskeletal Neuronal Interactions, vol. 5, no. 3, pp. 239-254, 2005.
148. J. P. Bonjour, "Protein intake and bone health", International Journal for Vitamin and Nutrition Research, vol. 81, no. 2-3, pp. 134-142, 2011.
149. A. Simkin, J. Ayalon, and I. Leichter, "Increased trabecular bone density due to bone-loading exercises in postmenopausal osteoporotic women", Calcified Tissue International, vol. 40, no. 2, pp. 59-63, 1987.
150. G. A. Kelley and K. S. Kelley, "Exercise and bone mineral density at the femoral neck in postmenopausal women: a metaanalysis of controlled clinical trials with individual patient data", American Journal of Obstetrics and Gynecology, vol. 194, no. 3, pp. 760-767, 2006.
151. M. Martyn-St James and S. Carroll, "A meta-analysis of impact exercise on postmenopausal bone loss: the case for mixed loading exercise programmes", British Journal of Sports Medicine, vol. 43, no. 12, pp. 898-908, 2009.
152. K. T. Borer, "Physical activity in the prevention and amelioration of osteoporosis in women: Interaction of mechanical, hormonal and dietary factors", Sports Medicine, vol. 35, no. 9, pp. 779-830, 2005.
153. K. Landin-Wilhelmsen, P. A. Lundberg, G. Lappas, and L. Wilhelmsen, "Insulin-like growth factor I levels in healthy adults", Hormone Research, vol. 62, supplement 1, pp. 8-16, 2004.
154. A. E. Bennett, H. W. Wahner, B. L. Riggs, and R. L. Hintz, "Insulin-like growth factors I and II: aging and bone density in women", Journal of Clinical Endocrinology and Metabolism, vol. 59, no. 4, pp. 701-704, 1984.
155. F. Callewaert, K. Venken, J. J. Kopchick et al., "Sexual dimorphism in cortical bone size and strength but not density is determined by independent and time-specific actions of sex steroids and IGF-1: evidence from pubertal mouse models", Journal of Bone and Mineral Research, vol. 25, no. 3, pp. 617-626, 2010.
156. Y. Wu, H. Sun, J. Basta-Pljakic et al., "Serum IGF-1 is insufficient to restore skeletal size in the total absence of the growth hormone receptor", Journal of Bone and Mineral Research, vol. 28, no. 7, pp. 1575-1586, 2013.
157. S. Bonadonna, A. Burattin, M. Nuzzo et al., "Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects", European Journal of Endocrinology, vol. 152, no. 2, pp. 199-205, 2005.
158. S. C. Manolagas and R. S. Weinstein, "New developments in the pathogenesis and treatment of steroid-induced osteoporosis", Journal of Bone and Mineral Research, vol. 14, no. 7, pp. 1061-1066, 1999.
159. K. Berneis, M. Oehri, M. Kraenzlin, and U. Keller, "Effects of IGF-I combined with GH on glucocorticoid-induced changes of bone and connective tissue turnover in man", Journal of Endocrinology, vol. 162, no. 2, pp. 259-264, 1999.
160. S. Melmed, "Acromegaly", The New England Journal of Medicine, vol. 322, no. 14, pp. 966-977, 1990.
161. S. Ezzat, S. Melmed, D. Endres, D. R. Eyre, and F. R. Singer, "Biochemical assessment of bone formation and resorption in acromegaly", Journal of Clinical Endocrinology and Metabolism, vol. 76, no. 6, pp. 1452-1457, 1993.
162. M. Marazuela, B. Astigarraga, M. J. Tabuenca, J. Estrada, F. Marin, and T. Lucas, "Serum bone Gla protein as a marker of bone turnover in acromegaly", Calcified Tissue International, vol. 52, no. 6, pp. 419-421, 1993.
163. A. Scillitani, C. Battista, I. Chiodini et al., "Bone mineral density in acromegaly: the effect of gender, disease activity and gonadal status", Clinical Endocrinology, vol. 58, no. 6, pp. 725-731, 2003.
164. H. Kotzmann, P. Bernecker, P. Hubsch et al., "Bone mineral density and parameters of bone metabolism in patients with acromegaly", Journal of Bone and Mineral Research, vol. 8, no. 4, pp. 459-466, 1993.
165. G. P. Lesse, W. D. Fraser, R. Farquharson, L. Hipkin, and J. P. Vora, "Gonadal status is an important determinant of bone density in acromegaly", Clinical Endocrinology, vol. 48, no. 1, pp. 59-65, 1998.
166. H. Kaji, T. Sugimoto, D. Nakaoka et al., "Bone metabolism and body composition in Japanese patients with active acromegaly", Clinical Endocrinology, vol. 55, no. 2, pp. 175-181, 2001.
167. P. J. Ho, L. M. Fig, A. L. Barkan, and B. Shapiro, "Bonemineral density of the axial skeleton in acromegaly", Journal of Nuclear Medicine, vol. 33, no. 9, pp. 1608-1612, 1992.
168. M. J. Kayath and J. G. H. Vieira, "Osteopenia occurs in a minority of patients with acromegaly and is predominant in the spine", Osteoporosis International, vol. 7, no. 3, pp. 226-230, 1997.
169. I. Chiodini, V. Trischitta, V. Carnevale, A. Liuzzi, and A. Scillitani, "Bone mineral density in acromegaly: does growth hormone excess protect against osteoporosis?" Journal of Endocrinological Investigation, vol. 24, no. 4, pp. 288-291, 2001.
170. M. Bolanowski, W. Wielgus, A. Milewicz, and R. Marciniak, "Axial bone mineral density in patients with acromegaly", Academic Radiology, vol. 7, no. 8, pp. 592-594, 2000.
171. W. Zgliczynski, M. Kochman, W. Misiorowski, and P. Zdunowski, "In acromegaly, increased bone mineral density (BMD) is determined by GH-excess, gonadal function and gender", Neuroendocrinology Letters, vol. 28, no. 5, pp. 621-628, 2007.
172. P. Vestergaard and L. Mosekilde, "Fracture risk is decreased in acromegaly-a potential beneficial effect of growth hormone", Osteoporosis International, vol. 15, no. 2, pp. 155-159, 2004.
173. N. R. Biermasz, N. A. T. Hamdy, A. M. Pereira, J. A. Romijn, and F. Roelfsema, "Long-term maintenance of the anabolic effects of GH on the skeleton in successful treated patients with acromegaly", European Journal of Endocrinology, vol. 152, no. 1, pp. 53-60, 2005.
174. P. Broulik, J. Kragstrup, L. Mosekilde, and F. Melsen, "Osteon cross-sectional size in the iliac crest. Variation in normals and patients with osteoporosis, hyperparathyroidism, acromegaly, hypothyroidism and treated epilepsia", Acta Pathologica et Microbiologica Scandinavica A: Pathology, vol. 90, no. 5, pp. 339-344, 1982.
175. J. Halse, F. Melsen, and L. Mosekilde, "Iliac crest bone mass and remodelling in acromegaly", Acta Endocrinologica, vol. 97, no. 1, pp. 18-22, 1981.
176. B. L. Riggs, R. V. Randall, H. W. Wahner, J. Jowsey, P. J. Kelly, and M. Singh, "The nature of the metabolic bone disorder in acromegaly.", The Journal of Clinical Endocrinology & Metabolism, vol. 34, no. 6, pp. 911-918, 1972.
177. G. Padova, G. Borzì, L. Incorvaia et al., "Prevalence of osteoporosis and vertebral fractures in acromegalic patients", Clinical Cases in Mineral and Bone Metabolism, vol. 8, no. 3, pp. 37-43, 2011.
178. M. Madeira, L. V. Neto, F. de Paula Paranhos Neto et al., "Acromegaly has a negative influence on trabecular bone, but not on cortical bone, as assessed by high-resolution peripheral quantitative computed tomography", Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 4, pp. 1734-1741, 2013.
179. T. Ueland, E. N. Ebbesen, J. S. Thomsen et al., "Decreased trabecular bone biomechanical competence, apparent density, IGF-II and IGFBP-5 content in acromegaly", European Journal of Clinical Investigation, vol. 32, no. 2, pp. 122-128, 2002.
180. S. Bonadonna, G. Mazziotti, M. Nuzzo et al., "Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women", Journal of Bone and Mineral Research, vol. 20, no. 10, pp. 1837-1844, 2005.
181. G. Mazziotti, A. Bianchi, T. Porcelli et al., "Vertebral fractures in patients with acromegaly: a 3-year prospective study", Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 8, pp. 3402-3410, 2013.
182. K. M. Claessen, H. M. Kroon, A. M. Pereira et al., "Progression of vertebral fractures despite long-term biochemical control of acromegaly: a prospective follow-up study", Journal of Clinical Endocrinology & Metabolism, vol. 98, no. 12, pp. 4808-4815, Dec. 2013.
183. G. Mazziotti, M. Gola, A. Bianchi et al., "Influence of diabetes mellitus on vertebral fractures in men with acromegaly", Endocrine, vol. 40, no. 1, pp. 102-108, 2011.
184. M. J. E. Wassenaar, N. R. Biermasz, N. A. T. Hamdy et al., "High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly", European Journal of Endocrinology, vol. 164, no. 4, pp. 475-483, 2011.
185. C. Battista, I. Chiodini, S. Muscarella et al., "Spinal volumetric trabecular bone mass in acromegalic patients: a longitudinal study", Clinical Endocrinology, vol. 70, no. 3, pp. 378-382, 2009.
186. S. Boutroy, M. L. Bouxsein, F. Munoz, and P. D. Delmas, "In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography", The Journal of Clinical Endocrinology & Metabolism, vol. 90, no. 12, pp. 6508-6515, 2005.
187. K. M. Nicks, S. Amin, E. J. Atkinson, B. L. Riggs, L. J. Melton III, and S. Khosla, "Relationship of age to bone microstructure independent of areal bone mineral density", Journal of Bone and Mineral Research, vol. 27, no. 3, pp. 637-644, 2012.
188. K. K. Nishiyama, H. M. Macdonald, H. R. Buie, D. A. Hanley, and S. K. Boyd, "Postmenopausal women with osteopenia have higher cortical porosity and thinner cortices at the distal radius and tibia thanwomenwithnormal aBMD: aninvivoHR-pQCT study", Journal of Bone and Mineral Research, vol. 25, no. 4, pp. 882-890, 2010.
189. T. Argoud, S. Boutroy, B. Claustrat, R. Chapurlat, and P. Szulc, "Association between sex steroid levels and bone microarchitecture in men: the STRAMBO study", The Journal of Clinical Endocrinology & Metabolism, vol. 99, no. 4, pp. 1400-1410, 2014.
190. S. J. Holmes, R. W. Whitehouse, R. Swindell, G. Economou, J. E. Adams, and S. M. Shalet, "Effect of growth hormone replacement on bone mass in adults with adult onset growth hormone deficiency", Clinical Endocrinology, vol. 42, no. 6, pp. 627-633, 1995.
191. G. Amato, G. Izzo, G. La Montagna, and A. Bellastella, "Low dose recombinant human growth hormone normalizes bone metabolism and cortical bone density and improves trabecular bone density in growth hormone deficient adults without causing adverse effects", Clinical Endocrinology, vol. 45, no. 1, pp. 27-32, 1996.
192. T. B. Hansen, K. Brixen, N. Vahl et al., "Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: a double blind, randomized, placebo-controlled study", Journal of Clinical Endocrinology and Metabolism, vol. 81, no. 9, pp. 3352-3359, 1996.
193. M. Thoren, M. Soop, M. Degerblad, and M. Saaf, "Preliminary study of the effects of growth hormone substitution therapy on bone mineral density and serum osteocalcin levels in adults with growth hormone deficiency", Acta Endocrinologica, vol. 128, supplement 2, pp. 41-43, 1993.
194. S. A. Beshyah, P. Kyd, E. Thomas, A. Fairney, and D. G. Johnston, "The effects of prolonged growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adult", Clinical Endocrinology, vol. 42, no. 3, pp. 249-254, 1995.
195. J. M. Gómez, N. Gómez, J. Fiter, and J. Soler, "Effects of long-term treatment with GH in the bone mineral density of adults with hypopituitarism and GH deficiency and after discontinuation of GH replacement", Hormone and Metabolic Research, vol. 32, no. 2, pp. 66-70, 2000.
196. H. Kotzmann, M. Riedl, P. Bernecker et al., "Effect of longterm growth-hormone substitution therapy on bone mineral density and parameters of bone metabolism in adult patients with growth hormone deficiency", Calcified Tissue International, vol. 62, no. 1, pp. 40-46, 1998.
197. J. Johansson, K. Landin, G. Johannsson, L. Tengborn, and B. Bengtsson, "Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults", Thrombosis and Haemostasis, vol. 76, no. 3, pp. 422-428, 1996.
198. G. Götherström, B. A. Bengtsson, I. Bossæus, G. Johansson, and J. Svensson, "Ten-year GH replacement increase bone mineral density in hypopituitary patients with adult onset GH deficiency", European Journal of Endocrinology, vol. 156, no. 1, pp. 55-64, 2007.
199. M. Elbornsson, G. Götherström, I. Bosæus, B. Bengtsson, G. Johannsson, and J. Svensson, "Fifteen years of GH replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency", European Journal of Endocrinology, vol. 166, no. 5, pp. 787-795, 2012.
200. G. Johannsson, T. Rosén, I. Bosaeus, L. Sjöström, and B. Bengtsson, "Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency", Journal of Clinical Endocrinology and Metabolism, vol. 81, no. 8, pp. 2865-2873, 1996.
201. G. Mazziotti, A. Bianchi, S. Bonadonna et al., "Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy", Journal of Bone and Mineral Research, vol. 21, no. 4, pp. 520-528, 2006.
202. M. Barake, A. Klibanski, and N. A. Tritos, "Effects of recombinant human growth hormone therapy on bone mineral density in adults with growth hormone deficiency: a meta-analysis", The Journal of Clinical Endocrinology & Metabolism, vol. 99, no. 3, pp. 852-860, 2014.
203. S. R. Cummings and L. J. Melton III, "Epidemiology and outcomes of osteoporotic fractures", The Lancet, vol. 359, no. 9319, pp. 1761-1767, 2002.
204. A. C. Looker, E. S. Orwoll, C. C. Johnston Jr. et al., "Prevalence of low femoral bone density in older U. S. adults from NHANES III", Journal of Bone and Mineral Research, vol. 12, no. 11, pp. 1761-1768, 1997.
205. Z. A. Cole, E. M. Dennison, and C. Cooper, "Osteoporosis epidemiology update", Current Rheumatology Reports, vol. 10, no. 2, pp. 92-96, 2008.
206. L. G. Raisz, "Pathogenesis of osteoporosis: concepts, conflicts, and prospects", Journal of Clinical Investigation, vol. 115, no. 12, pp. 3318-3325, 2005.
207. S. Khosla and B. L. Riggs, "Pathophysiology of age-related bone loss and osteoporosis", Endocrinology and Metabolism Clinics of North America, vol. 34, no. 4, pp. 1015-1030, 2005.
208. S. Perrini, L. Laviola, M. C. Carreira, A. Cignarelli, A. Natalicchio, and F. Giorgino, "The GH/IGF1 axis and signaling pathways in the muscle and bone: mechanisms underlying agerelated skeletal muscle wasting and osteoporosis", Journal of Endocrinology, vol. 205, no. 3, pp. 201-210, 2010.
209. E. Seeman, "Pathogenesis of bone fragility in women and men", The Lancet, vol. 359, no. 9320, pp. 1841-1850, 2002.
210. S. Khosla, L. J. Melton III, and B. L. Riggs, "The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed?" Journal of Bone and Mineral Research, vol. 26, no. 3, pp. 441-451, 2011.
211. P. Garnero, E. Sornay-Rendu, M. C. Chapuy, and P. D. Delmas, "Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis", Journal of Bone and Mineral Research, vol. 11, no. 3, pp. 337-349, 1996.
212. M. T. Hannan, D. T. Felson, B. Dawson-Hughes et al., "Risk factors for longitudinal bone loss in elderly men andwomen: the Framingham Osteoporosis Study", Journal of Bone and Mineral Research, vol. 15, no. 4, pp. 710-720, 2000.
213. C. Cooper, G. Campion, and L. J. Melton III, "Hip fractures in the elderly: a world-wide projection", Osteoporosis International, vol. 2, no. 6, pp. 285-289, 1992.
214. H. Burger, P. L. A. van Daele, K. Grashuis et al., "Vertebral deformities and functional impairment in men and women", Journal of Bone and Mineral Research, vol. 12, no. 1, pp. 152-157, 1997.
215. M. Thomas-John, M. B. Codd, S. Manne, N. B. Watts, and A. Mongey, "Risk factors for the development of osteoporosis and osteoporotic fractures among older men", Journal of Rheumatology, vol. 36, no. 9, pp. 1947-1952, 2009.
216. S. C. Manolagas, "From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis", Endocrine Reviews, vol. 31, no. 3, pp. 266-300, 2010.
217. G. A. Ledger, M. F. Burritt, P. C. Kao, W. M. O'Fallon, B. L. Riggs, and S. Khosla, "Role of parathyroid hormone in mediating nocturnal and age-related increases in bone resorption", Journal of Clinical Endocrinology & Metabolism, vol. 80, no. 11, pp. 3304-3310, 1995.
218. V. Nicolas, A. Prewett, P. Bettica et al., "Age-related decreases in insulin-like growth factor-I and transforming growth factor-β in femoral cortical bone from both men and women: implications for bone loss with aging", Journal of Clinical Endocrinology and Metabolism, vol. 78, no. 5, pp. 1011-1016, 1994.
219. S. Ljunghall, A. G. Johansson, P. Burman, O. Kampe, E. Lindh, and F. A. Karlsson, "Low plasma levels of insulin-like growth factor 1 (IGF-1) in male patients with idiopathic osteoporosis", Journal of Internal Medicine, vol. 232, no. 1, pp. 59-64, 1992.
220. L. Maïmoun, O. Coste, F. Galtier et al., "Bone mineral density acquisition in peripubertal female rhythmic gymnasts is directly associated with plasma IGF1/IGF-binding protein 3 ratio", European Journal of Endocrinology, vol. 163, no. 1, pp. 157-164, 2010.
221. S. Boonen, E. Lesaffre, J. Dequeker et al., "Relationship between baseline insulin-like growth factor-I (IGF-I) and femoral bone density in women aged over 70 years: potential implications for the prevention of age-related bone loss", Journal of the American Geriatrics Society, vol. 44, no. 11, pp. 1301-1306, 1996.
222. C. Wuster, W. F. Blum, S. Schlemilch, M. B. Ranke, and R. Ziegler, "Decreased serum levels of insulin-like growth factors and IGF binding protein 3 in osteoporosis", Journal of Internal Medicine, vol. 234, no. 3, pp. 249-255, 1993.
223. S. Khosla, E. J. Atkinson, L. J. Melton III, and B. L. Riggs, "Effects of age and estrogen status on serum parathyroid hormone levels and biochemical markers of bone turnover in women: a population-based study", The Journal of Clinical Endocrinology & Metabolism, vol. 82, no. 5, pp. 1522-1527, 1997.
224. J. P. T. Span, G. F. F. M. Pieters, C. G. J. Sweep, A. R. M. M. Hermus, and A. G. H. Smals, "Gender difference in insulin-like growth factor I response to growth hormone (GH) treatment in GH-deficient adults: Role of sex hormone replacement", Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 3, pp. 1121-1125, 2000.
225. B. C. Nindl, M. Santtila, J. Vaara, K. Hakkinen, and H. Kyrolainen, "Circulating IGF-I is associated with fitness and health outcomes in a population of 846 young healthy men", Growth Hormone and IGF Research, vol. 21, no. 3, pp. 124-128, 2011.
226. W. J. Kraemer, C. Dunn-Lewis, B. A. Comstock, G. A. Thomas, J. E. Clark, and B. C. Nindl, "Growth hormone, exercise, and athletic performance: a continued evolution of complexity", Current Sports Medicine Reports, vol. 9, no. 4, pp. 242-252, 2010.
227. S. M. Gregory, B. A. Spiering, J. A. Alemany et al., "Exerciseinduced insulin-like growth factor I systemconcentrations after training inwomen", Medicine and Science in Sports and Exercise, vol. 45, no. 3, pp. 420-428, 2013.
228. P. C. Henning, D. E. Scofield, K. R. Rarick et al., "Effects of acute caloric restriction compared to caloric balance on the temporal response of the IGF-I system", Metabolism: Clinical and Experimental, vol. 62, no. 2, pp. 179-187, 2013.
229. T. Chevalley, P. Hoffmeyer, J. Bonjour, and R. Rizzoli, "Early serum IGF-I response to oral protein supplements in elderly women with a recent hip fracture", Clinical Nutrition, vol. 29, no. 1, pp. 78-83, 2010.
230. A. L. Darling, D. J. Millward, D. J. Torgerson, C. E. Hewitt, and S. A. Lanham-New, "Dietary protein and bone health: a systematic review and meta-analysis", The American Journal of Clinical Nutrition, vol. 90, no. 6, pp. 1674-1692, 2009.
231. C. Franceschi, M. Bonafè, S. Valensin et al., "Inflamm-aging. An evolutionary perspective on immunosenescence", Annals of the New York Academy of Sciences, vol. 908, pp. 244-254, 2000.
232. M. S. Nanes, "Tumor necrosis factor-alpha: Molecular and cellular mechanisms in skeletal pathology", Gene, vol. 321, no. 1-2, pp. 1-15, 2003.
233. E. C. Wahl, J. Aronson, L. Liu et al., "Restoration of regenerative osteoblastogenesis in aged mice: modulation of TNF", Journal of Bone and Mineral Research, vol. 25, no. 1, pp. 114-123, 2010.
234. S. Boonen, E. Lesaffre, J. Aerssens, W. Pelemans, J. Dequeker, and R. Bouillon, "Deficiency of the growth hormone-insulinlike growth factor-1 axis potentially involved in age-related alterations in body composition", Gerontology, vol. 42, no. 6, pp. 330-338, 1996.
235. J. D. Veldhuis and C. Y. Bowers, "Human GH pulsatility: an ensemble property regulated by age and gender", Journal of Endocrinological Investigation, vol. 26, no. 9, pp. 799-813, 2003.
236. C. A. Benbassat, K. C. Maki, and T. G. Unterman, "Circulating levels of insulin-like growth factor (IGF) binding protein-1 and -3 in aging men: relationships to insulin, glucose, IGF, and dehydroepiandrosterone sulfate levels and anthropometric measures", Journal of Clinical Endocrinology and Metabolism, vol. 82, no. 5, pp. 1484-1491, 1997.
237. M. Nasu, T. Sugimoto, M. Chihara, M. Hiraumi, F. Kurimoto, and K. Chihara, "Effect of natural menopause on serumlevels of IGF-I and IGF-binding proteins: Relationship with bone mineral density and lipid metabolism in perimenopausal women", European Journal of Endocrinology, vol. 136, no. 6, pp. 608-616, 1997.
238. E. Romagnoli, S. Minisola, V. Carnevale et al., "Circulating levels of insulin-like growth factor binding protein 3 (IGFBP-3) and insulin-like growth factor I (IGF-I) in perimenopausal women", Osteoporosis International, vol. 4, no. 6, pp. 305-308, 1994.
239. M. Muñoz-Torres, P. Mezquita-Raya, F. Lopez-Rodriguez, E. Torres-Vela, J. de Dios Luna, and F. Escobar-Jimenez, "The contribution of IGF-I to skeletal integrity in postmenopausal women", Clinical Endocrinology, vol. 55, no. 6, pp. 759-766, 2001.
240. P. Gillberg, H. Olofsson, H. Mallmin, W. F. Blum, S. Ljunghall, and A. G. Nilsson, "Bone mineral density in femoral neck is positively correlated to circulating insulin-like growth factor (IGF)-I and IGF-binding protein (IGFBP)-3 in Swedish men", Calcified Tissue International, vol. 70, no. 1, pp. 22-29, 2002.
241. H. P. Kruse and F. Kuhlencordt, "On an attempt to treat primary and secondary osteoporosis with human growth hormone", Hormone and Metabolic Research, vol. 7, no. 6, pp. 488-491, 1975.
242. K. Brixen, H. K. Nielsen, L. Mosekilde, and A. Flyvbjerg, "A short course of recombinant human growth hormone treatment stimulates osteoblasts and activates bone remodeling in normal human volunteers", Journal of Bone and Mineral Research, vol. 5, no. 6, pp. 609-618, 1990.
243. D. Rudman, A. G. Feller, H. S. Nagraj et al., "Effects of human growth hormone in men over 60 years old", The New England Journal of Medicine, vol. 323, no. 1, pp. 1-6, 1990.
244. L. Holloway, G. Butterfield, R. L. Hintz, N. Gesundheit, and R. Marcus, "Effects of recombinant human growth hormone on metabolic indices, body composition, and bone turnover in healthy elderly women", Journal of Clinical Endocrinology and Metabolism, vol. 79, no. 2, pp. 470-479, 1994.
245. T. Bianda, M. A. Hussain, Y. Glatz, R. Bouillon, E. R. Froesch, and C. Schmid, "Effects of short-term insulin-like growth factor-I or growth hormone treatment on bone turnover, renal phosphate reabsorption and 1, 25 dihydroxyvitamin D3 production in healthy man", Journal of Internal Medicine, vol. 241, no. 2, pp. 143-150, 1997.
246. B. Clemmesen, K. Overgaard, B. Riis, and C. Christiansen, "Human growth hormone and growth hormone releasing hormone: a double-masked, placebo-controlled study of their effects on bone metabolism in elderly women", Osteoporosis International, vol. 3, no. 6, pp. 330-336, 1993.
247. M. Kassem, K. Brixen, W. Blum, L. Mosekilde, and E. F. Eriksen, "No evidence for reduced spontaneous or growth-hormonestimulated serum levels of insulin-like growth factor (IGF) - I, IGF-II or IGF binding protein 3 in women with spinal osteoporosis", European Journal of Endocrinology, vol. 131, no. 2, pp. 150-155, 1994.
248. R. J. Erdtsieck, H. A. P. Pols, N. K. Valk et al., "Treatment of post-menopausal osteoporosis with a combination of growth hormone and pamidronate: a placebo controlled trial", Clinical Endocrinology, vol. 43, no. 5, pp. 557-565, 1995.
249. L. Holloway, L. Kohlmeier, K. Kent, and R. Marcus, "Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women", Journal of Clinical Endocrinology and Metabolism, vol. 82, no. 4, pp. 1111-1117, 1997.
250. M. Kassem, K. Brixen, L. Mosekilde, W. F. Blum, and A. Flyvbjerg, "Effects of growth hormone treatment on serum levels of insulin-like growth factors (IGFs) and IGF binding proteins 1-4 in postmenopausal women", Clinical Endocrinology, vol. 49, no. 6, pp. 747-756, 1998.
251. T. Sugimoto, D. Nakaoka, M. Nasu, M. Kanzawa, T. Sugishita, and K. Chihara, "Effect of recombinant human growth hormone in elderly osteoporotic women", Clinical Endocrinology, vol. 51, no. 6, pp. 715-724, 1999.
252. M. Sääf, A. Hilding, M. Thorén, S. Troell, and K. Hall, "Growth hormone treatment of osteoporotic postmenopausal women - a one-year placebo-controlled study", European Journal of Endocrinology, vol. 140, no. 5, pp. 390-399, 1999.
253. T. Sugimoto, H. Kaji, D. Nakaoka et al., "Effect of low-dose of recombinant human growth hormone on bone metabolism in elderly women with osteoporosis", European Journal of Endocrinology, vol. 147, no. 3, pp. 339-348, 2002.
254. P. Gillberg, H. Mallmin, M. Petrén-Mallmin, S. Ljunghall, and A. G. Nilsson, "Two years of treatment with recombinant human growth hormone increases bone mineral density inmen with idiopathic osteoporosis", Journal of Clinical Endocrinology & Metabolism, vol. 87, no. 11, pp. 4900-4906, 2002.
255. K. Landin-Wilhelmsen, A. Nilsson, I. Bosaeus, and B. Bengtsson, "Growth hormone increases bone mineral content in postmenopausal osteoporosis: a randomized placebo-controlled trial", Journal of Bone and Mineral Research, vol. 18, no. 3, pp. 393-405, 2003.
256. F. Joseph, A. M. Ahmad, M. Ul-Haq et al., "Effects of growth hormone administration on bone mineral metabolism, PTH sensitivity and PTH secretory rhythm in postmenopausal women with established osteoporosis", Journal of Bone and Mineral Research, vol. 23, no. 5, pp. 721-729, 2008.
257. A. G. Johansson, E. Lindh, W. F. Blum, G. Kollerup, O. H. Sørensen, and S. Ljunghall, "Effects of growth hormone and insulin-like growth factor I in men with idiopathic osteoporosis", Journal of Clinical Endocrinology and Metabolism, vol. 81, no. 1, pp. 44-48, 1996.
258. H. D. White, A. M. Ahmad, B. H. Durham et al., "Growth hormone replacement is important for the restoration of parathyroid hormone sensitivity and improvement in bone metabolism in older adult growth hormone-deficient patients", Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 6, pp. 3371-3380, 2005.
259. K. K. Y. Ho and A. J. Weissberger, "Impact of short-term estrogen administration on growth hormone secretion and action: distinct route-dependent effects on connective and bone tissue metabolism", Journal of Bone and Mineral Research, vol. 7, no. 7, pp. 821-827, 1992.
260. R. Marcus, G. Butterfield, L. Holloway et al., "Effects of short term administration of recombinant human growth hormone to elderly people", Journal of Clinical Endocrinology and Metabolism, vol. 70, no. 2, pp. 519-527, 1990.
261. T. L. Bianda, "Effects of growth hormone (GH) and insulinlike growth factor-I on serum leptin in GH-deficient adults", Diabetologia, vol. 40, no. 3, pp. 363-364, 1997.
262. A. G. Johansson, E. Lindh, and S. Ljunghall, "Insulin-like growth factor I stimulates bone turnover in osteoporosis", The Lancet, vol. 339, no. 8809, article 1619, 1992.
263. P. R. Ebeling, J. D. Jones, W. M. O'Fallon, C. H. Janes, and B. L. Riggs, "Short-term effects of recombinant human insulin-like growth factor I on bone turnover in normal women", Journal of Clinical Endocrinology and Metabolism, vol. 77, no. 5, pp. 1384-1387, 1993.
264. C. D. Rubin, B. Reed, K. Sakhaee, and C. Y. C. Pak, "Treating a patient with the Werner syndrome and osteoporosis using recombinant human insulin-like growth factor", Annals of Internal Medicine, vol. 121, no. 9, pp. 665-668, 1994.
265. S. K. Grinspoon, H. B. A. Baum, S. Peterson, and A. Klibanski, "Effects of rhIGF-I administration on bone turnover during short-term fasting", Journal of Clinical Investigation, vol. 96, no. 2, pp. 900-906, 1995.
266. L. J. Ghiron, J. L. Thompson, L. Holloway et al., "Effects of recombinant insulin-like growth factor-I and growth hormone on bone turnover in elderly women", Journal of Bone and Mineral Research, vol. 10, no. 12, pp. 1844-1852, 1995.
267. S. Grinspoon, H. Baum, K. Lee, E. Anderson, D. Herzog, and A. Klibanski, "Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa", Journal of Clinical Endocrinology and Metabolism, vol. 81, no. 11, pp. 3864-3870, 1996.
268. N. Mauras, S. Q. Doi, and J. R. Shapiro, "Recombinant human insulin-like growth factor I, recombinant human growth hormone, and sex steroids: effects on markers of bone turnover in humans", Journal of Clinical Endocrinology and Metabolism, vol. 81, no. 6, pp. 2222-2226, 1996.
269. A. L. Friedlander, G. E. Butterfield, S. Moynihan et al., "One year of insulin-like growth factor I treatment does not affect bone density, body composition, or psychological measures in postmenopausal women", The Journal of Clinical Endocrinology & Metabolism, vol. 86, no. 4, pp. 1496-1503, 2001.
270. S. Boonen, C. Rosen, R. Bouillon et al., "Musculoskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteoporotic patients with proximal femoral fracture: a double-blind, placebo-controlled pilot study", Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 4, pp. 1593-1599, 2002.
271. S. Grinspoon, L. Thomas, K. Miller, D. Herzog, and A. Klibanski, "Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa", Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 6, pp. 2883-2891, 2002.
272. S. Grinspoon, K. Miller, D. Herzog, D. Clemmons, and A. Klibanski, "Effects of recombinant human insulin-like growth factor (IGF)-I and estrogen administration on IGF-I, IGF binding protein (IGFBP)-2, and IGFBP-3 in anorexia nervosa: a randomized-controlled study", Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 3, pp. 1142-1149, 2003.
273. M. Misra, J. McGrane, K. K. Miller et al., "Effects of rhIGF-1 administration on surrogate markers of bone turnover in adolescents with anorexia nervosa", Bone, vol. 45, no. 3, pp. 493-498, 2009.
274. A. J. van der Lely, S. W. Lamberts, K. W. Jauch et al., "Use of human GH in elderly patients with accidental hip fracture", European Journal of Endocrinology, vol. 143, no. 5, pp. 585-592, 2000.
275. A.-L. Yeo, D. Levy, F. C. Martin et al., "Frailty and the biochemical effects of recombinant human growth hormone in womenafter surgery for hipfracture", Growth Hormone and IGF Research, vol. 13, no. 6, pp. 361-370, 2003.
276. A. J. Weissberger, A. D. Anastasiadis, I. Sturgess, F. C. Martin, M. A. Smith, and P. H. Sönksen, "Recombinant human growth hormone treatment in elderly patients undergoing elective total hip replacement", Clinical Endocrinology, vol. 58, no. 1, pp. 99-107, 2003.
277. M. Hedström, M. Sääf, E. Brosjö et al., "Positive effects of shortterm growth hormone treatment on lean body mass and BMC after a hip fracture: a double-blind placebo-controlled pilot study in 20 patients", Acta Orthopaedica Scandinavica, vol. 75, no. 4, pp. 394-401, 2004.
278. M. Raschke, M. Højby Rasmussen, S. Govender, D. Segal, M. Suntum, and J. S. Christiansen, "Effects of growth hormone in patients with tibial fracture: a randomised, doubleblind, placebo-controlled clinical trial", European Journal of Endocrinology, vol. 156, no. 3, pp. 341-351, 2007.
279. T. Krusenstjerna-Hafstrøm, M. H. Rasmussen, M. Raschke, S. Govender, J. Madsen, and J. S. Christiansen, "Biochemical markers of bone turnover in tibia fracture patients randomly assigned to growth hormone (GH) or placebo injections. Implications for detection of GH abuse", Growth Hormone and IGF Research, vol. 21, no. 6, pp. 331-335, 2011.
280. A. G. Johansson, E. Lindh, G. Kollerup, and S. Ljunghal, "Dosedependent of IGF-1 on the metabolism of collagen type I in male osteoporosis", Journal of Bone and Mineral Research, vol. 10, article S393, 1995.
281. A. V. Papavasiliou, "Histological and biological changes in the epiphyseal plate during fracture healing", Journal of Orthopaedic Science, vol. 7, no. 1, pp. 91-96, 2002.
282. M. A. Mont, L. C. Jones, T. A. Einhorn, D. S. Hungerford, and A. H. Reddi, "Osteonecrosis of the femoral head: potential treatment with growth and differentiation factors", Clinical Orthopaedics and Related Research, no. 355, pp. S314-S335, 1998.
283. S. N. Lissenberg-Thunnissen, D. J. J. de Gorter, C. F. M. Sier, and I. B. Schipper, "Use and efficacy of bonemorphogenetic proteins in fracture healing", International Orthopaedics, vol. 35, no. 9, pp. 1271-1280, 2011.
284. H. Bail, M. J. Raschke, S. F. Kolbeck, A. Weiler, P. M. Haahr, and N. P. Haas, "Recombinant growth hormone increasus callus maturation time in distraction osteogenesis-a histomorphometric study", Langenbecks Archiv für Chirurgie, vol. 115, supplement I, pp. 675-680, 1998.
285. S. D. Cook, G. C. Baffes, M. W. Wolfe, T. K. Sampath, D. C. Rueger, and T. S. Whitecloud III, "The effect of recombinant human osteogenic protein-1 on healing of large segmental bone defects", Journal of Bone and Joint Surgery A, vol. 76, no. 6, pp. 827-838, 1994.
286. H. Kawaguchi, T. Kurokawa, K. Hanada et al., "Stimulation of fracture repair by recombinant human basic fibroblast growth factor in normal and streptozotocin-diabetic rats", Endocrinology, vol. 135, no. 2, pp. 774-781, 1994.
287. H. M. Nielsen, B. Bak, P. H. Jorgensen, and T. T. Andreassen, "Growth hormone promotes healing of tibial fractures in the rat", Acta Orthopaedica Scandinavica, vol. 62, no. 3, pp. 244-247, 1991.
288. T. J. Nash, C. R. Howlett, C. Martin, J. Steele, K. A. Johnson, and D. J. Hicklin, "Effect of platelet-derived growth factor on tibial osteotomies in rabbits", Bone, vol. 15, no. 2, pp. 203-208, 1994.
289. R. F. Spencer, "The effect of head injury on fracture healing. A quantitative assessment", Journal of Bone and Joint Surgery B, vol. 69, no. 4, pp. 525-528, 1987.
290. S. M. Bidner, I. M. Rubins, J. V. Desjardins, D. J. Zukor, and D. Goltzman, "Evidence for a humoral mechanism for enhanced osteogenesis after head injury", Journal of Bone and Joint Surgery, vol. 72, no. 8, pp. 1144-1149, 1990.
291. D. Gazit, M. Karmish, L. Holzman, and I. Bab, "Regenerating marrow induces systemic increase in osteo- and chondrogenesis", Endocrinology, vol. 126, no. 5, pp. 2607-2613, 1990.
292. S. Weiss, P. Henle, M. Bidlingmaier, A. Moghaddam, P. Kasten, and G. Zimmermann, "Systemic response of the GH/IGF-I axis in timely versus delayed fracture healing", Growth Hormone and IGF Research, vol. 18, no. 3, pp. 205-212, 2008.
293. M. di Monaco, F. Vallero, R. Di Monaco, R. Tappero, and A. Cavanna, "Serum levels of insulin-like growth factor-I are positively associated with functional outcome after hip fracture in elderly women", The American Journal of Physical Medicine and Rehabilitation, vol. 88, no. 2, pp. 119-125, 2009.
294. G. Johannsson and C. Ohlsson, "Growth hormone therapy and fracture risk in the growth hormone-deficient adult", Bailliere's Clinical Endocrinology and Metabolism, vol. 12, no. 2, pp. 233-250, 1998.
295. S. Yang, L. Cao, S. Cai, J. Yuan, and J. Wang, "Asystematic review of growth hormone for hip fractures", Growth Hormone and IGF Research, vol. 22, no. 3-4, pp. 97-101, 2012.
296. B. R. Bistrian, J. Schwartz, and N. W. Istfan, "Cytokines, muscle proteolysis, and the catabolic response to infection and inflammation", Proceedings of the Society for Experimental Biology and Medicine, vol. 200, no. 2, pp. 220-223, 1992.
297. D. W. Wilmore, "Catabolic illness: Strategies for enhancing recovery", The New England Journal of Medicine, vol. 325, no. 10, pp. 695-702, 1991.
298. R. N. Cooney and M. Shumate, "The inhibitory effects of interleukin-1 on growth hormone action during catabolic illness", Vitamins & Hormones, vol. 74, pp. 317-340, 2006.
299. S. von Laue and R. J. M. Ross, "Inflammatory cytokines and acquired growth hormone resistance", Growth Hormone and IGF Research, vol. 10, S9, p. S14, 2000.
300. G. Yumet, M. L. Shumate, D. P. Bryant, C. H. Lang, and R. N. Cooney, "Hepatic growth hormone resistance during sepsis is associated with increased suppressors of cytokine signaling expression and impaired growth hormone signaling", Critical Care Medicine, vol. 34, no. 5, pp. 1420-1427, 2006.
301. G. Yumet, M. L. Shumate, P. Bryant, C. Lin, C. H. Lang, and R. N. Cooney, "Tumor necrosis factor mediates hepatic growth hormone resistance during sepsis", American Journal of Physiology: Endocrinology and Metabolism, vol. 283, no. 3, pp. E472-E481, 2002.
302. T. A. Ahmed, M. D. Buzzelli, C. H. Lang et al., "Interleukin-6 inhibits growth hormone-mediated gene expression in hepatocytes", American Journal of Physiolog: Gastrointestinal and Liver Physiology, vol. 292, no. 6, pp. G1793-G1803, 2007.
303. A. A. Samani, S. Yakar, D. Le Roith, and P. Brodt, "The role of the IGF system in cancer growth and metastasis: overview and recent insights", Endocrine Reviews, vol. 28, no. 1, pp. 20-47, 2007.
304. E. Seccareccia and P. Brodt, "The role of the insulin-like growth factor-I receptor in malignancy: an update", Growth Hormone & IGF Research, vol. 22, no. 6, pp. 193-199, 2012.
305. A. Deodati, B. B. Ferroli, and S. Cianfarani, "Association between growth hormone therapy and mortality, cancer and cardiovascular risk: systematic review and meta-analysis", Growth Hormone and IGF Research, 2014.
306. J. C. Carel, E. Ecosse, F. Landier et al., "Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study", Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 2, pp. 416-425, 2012.
307. L. Sävendahl, M. Maes, K. Albertsson-Wikland et al., "Longterm mortality and causes of death in isolated GHD, ISS, and SGApatients treatedwith recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: Preliminary report of 3 countries participating in the EUSAGhE study", Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 2, pp. E213-E217, 2012.
308. S. Pekic and V. Popovic, "GH therapy and cancer risk in hypopituitarism: what we know fromhuman studies", European Journal of Endocrinology, vol. 169, no. 5, pp. R89-R97, 2013.
309. B. Ergun-Longmire, A. C. Mertens, P. Mitby et al., "Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor", Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 9, pp. 3494-3498, 2006.
310. V. Popovic, A. F. Mattsson, R. C. Gaillard, P. Wilton, M. Kołtowska-Häggström, and M. B. Ranke, "Serum insulin-like growth factor I (IGF-I), IGF-binding proteins 2 and 3, and the risk for development of malignancies in adults with growth hormone (GH) deficiency treated with GH: data from KIMS (Pfizer International Metabolic Database)", Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 9, pp. 4449-4454, 2010.
311. H. Xiang, Y. Wang, and S. Nie, "Meta-analysis of the association between insulin-like growth factor binding protein 3 genetic polymorphisms and colorectal cancer susceptibility", PLoS ONE, vol. 8, no. 3, Article ID e59665, 2013.
312. K. Chihara, Y. Kato, H. Kohno et al., "Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD)", Growth Hormone and IGF Research, vol. 18, no. 4, pp. 307-317, 2008.
313. N. Mauras, A. D. Rogol, M. W. Haymond, and J. D. Veldhuis, "Sex steroids, growth hormone, insulin-like growth factor-1: neuroendocrine andmetabolic regulation in puberty", Hormone Research, vol. 45, no. 1-2, pp. 74-80, 1996.
314. S. Khosla, L. J. Melton, and B. L. Riggs, "Estrogens and bone health in men", Calcified Tissue International, vol. 69, no. 4, pp. 189-192, 2001.